Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2014-08-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) and covers the financial performance for the second quarter and first half of 2014 (2014-04-01 to 2014-06-30). It contains detailed financial statements, including income statements, cash flow, and balance sheet data, as well as management commentary on business operations, research projects, and risks. This fits the definition of an Interim/Quarterly Report (IR). H1 2014
2014-08-20 Swedish
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT' and provides comprehensive financial data, including income statements, cash flow, and balance sheet information for the second quarter and the first six months of 2014. It includes detailed management commentary, business highlights, and financial analysis, which fits the definition of an Interim/Quarterly Report (IR). H1 2014
2014-08-20 English
Audit Report / Information 2013
Audit Report / Information Classification · 1% confidence The document is titled "ÅRSREDOVISNING" (Annual Report in Swedish) and contains a detailed Table of Contents listing sections typical of an annual report, such as 'VD har ordet' (CEO's statement), 'Flerårsöversikt' (Multi-year overview), 'Förvaltningberättelse' (Directors' Report), 'Finansiella rapporter' (Financial reports), 'Koncernens rapport över totalresultat' (Group statement of comprehensive income), 'Koncernens rapport över finansiell ställning' (Group statement of financial position), and 'Revisionsberättelse' (Auditor's Report). The length (284,396 characters) is substantial, indicating a full report rather than a brief announcement. Although the company is Swedish, the content structure strongly aligns with the comprehensive annual reporting requirements, making '10-K' (the standard US equivalent for a comprehensive annual report) the most appropriate classification among the provided options, as 'AR' (Audit Report/Information) is usually reserved for standalone audit documents, and 'IR' (Interim Report) is for shorter periods. Given the comprehensive nature covering the entire fiscal year, it is classified as an Annual Report. FY 2013
2014-08-20 Swedish
Annual Report 2013
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT' and contains a comprehensive table of contents covering CEO statements, financial summaries, statutory administration reports, corporate governance, and full financial statements (Consolidated Statement of Comprehensive Income, Balance Sheet, etc.). It is a full-year report for NeuroVive Pharmaceutical AB, fitting the definition of a 10-K (Annual Report). FY 2013
2014-08-20 English
Enrollment to phase II study on NeuroSTAT® continues
Regulatory Filings Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and dated August 14, 2014. It provides an update on the enrollment status of a clinical phase IIa study for NeuroSTAT® and includes a summary of the company's product pipeline (CicloMulsion®, NeuroSTAT®, NVP018, NVP019). This format—a brief announcement detailing operational or clinical progress, often released outside of standard quarterly reporting cycles—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it focuses on operational updates (enrollment progress) rather than comprehensive financial statements (like a 10-K or IR), and it is a formal press release, it fits best as an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less focused on operational results. Given the content focuses on clinical trial progress and pipeline status, which often accompanies or substitutes for detailed financial reporting in biotech/pharma, ER is the most appropriate fit among the specific options, as it is an 'initial announcement' of operational status. However, upon reviewing the definitions, 'ER' is for 'quarterly/periodical financial results (key highlights only)'. This document is purely operational/clinical progress. It is a formal press release required to be published under Swedish law. Since it doesn't fit perfectly into ER (no financials mentioned) or IR (not comprehensive interim report), and it's not announcing the publication of another report (RPA), the best fit is the general regulatory announcement category, RNS, as it is a mandatory public disclosure of material information. Revisiting the definitions: It is a 'NEWS RELEASE' announcing operational progress. If it were a formal financial report, it would be 10-K or IR. Since it is a general announcement of material, non-financial operational news, RNS (Regulatory Filings / General regulatory announcements) is the most suitable fallback category.
2014-08-14 English
Fortsatt rekrytering till klinisk fas II-studie med NeuroSTAT®
Regulatory Filings Classification · 1% confidence The document is titled "PRESS SMEDDE ELANDE" (Press Release) and is dated August 14, 2014. It provides updates on the ongoing clinical studies for their drug candidates (NeuroSTAT® and CicloMulsion®), including recruitment status, interim analysis plans, and future milestones. It also details other pipeline products (NVP018, NVP019). This structure—a formal announcement detailing operational and clinical progress, often released outside of scheduled earnings reports—is characteristic of a general regulatory announcement or press release regarding company activities. Since it is not a full Annual Report (10-K), a specific Earnings Release (ER), or a detailed Interim Report (IR), and it serves as a general update on company status, the most appropriate classification is Regulatory Filings (RNS), which acts as a general category for such announcements that don't fit elsewhere, or potentially a Report Publication Announcement (RPA) if it were announcing the release of a separate, attached report. Given the content is the update itself, RNS is the best fit as a general regulatory disclosure.
2014-08-14 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.